Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs APX 005M (Primary)
- Indications Glioma
- Focus Adverse reactions; Pharmacokinetics
- 02 Feb 2018 Status changed from not yet recruiting to recruiting.
- 30 Jan 2018 Status changed from active, no longer recruiting to not yet recruiting.
- 08 Jan 2018 New trial record